GSK hits trouble with Trelegy as EU regulators block asthma indication
European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups. It’s a blow for GSK, which hopes that Trelegy (fluticasone furoate+umeclidinium+vilanterol) will help to revive the… Read More »GSK hits trouble with Trelegy as EU regulators block asthma indication